The good news coming out of the Medtronic earnings announcement is that results confirmed what we already knew. Namely the Control IQ from Tandem is eating the 670G for lunch and as we predicted would adversely impact Medtronic sales. Now this isn’t likely what Medtronic wanted but it is the truth.
Looking at the Medtronic results it’s difficult to find a bright spot. Sales declined in the US by low double digits which was partially offset by growth in international markets. This sounds good on the surface until one considers that when it comes to insulin pump therapy . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.